Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Abstract: The present invention relates to manufacturing processes for the preparation of a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil and optionally at least one diuretic characterized in that nifedipine is released in the body in a controlled (modified) manner and the candesartan cilexetil is released rapidly (immediate release (IR)) and optionally the diuretic is released rapidly (immediate release (IR)) and the pharmaceutical dosage forms obtainable by these processes.

Abstract: Methods for improving solubility and bioavailability of lipophilic compounds are described. Particularly, described are stabilized supersaturated solid solutions, particularly in power from, of lipophilic drugs, such as steroidal molecules.

Abstract: The present invention relates to a coated pharmaceutical composition containing regorafenib, a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating disorders.

Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain an Estrogen Receptor beta (ER-?) selective agonist. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.

Abstract: The present invention relates to small stabilised particles comprising a crystalline form of an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate and at least one protective agent. Such particles confer stability to the alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate, and is conveniently incorporated in unit dosage forms, such as wafers.

Abstract: The present invention describes drug delivery compositions in the form of thin water-soluble films (wafers), which contain particles that comprise at least one active ingredient—which is not an estrogen and/or a progestin and/or an alkaline earth metal salt of 5-methyl-(6S)-tetrahydrofolate—and at least one protective agent. The protective agent provides effective taste-masking of the active ingredient due to limited release of the active ingredient in the mouth. The active ingredient is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route. The particles contained in the wafer provided by the present invention have a particle size of below 40 ?m thereby resulting in an acceptable sensation in the mouth while dissolving. Such wafers are especially suitable for pediatric use.

Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

Abstract: The present invention relates to drug delivery compositions in the form of thin water-soluble films (wafers), which contain small particles that comprise at least one progestin and at least one protective agent. The protective agent provides effective taste-masking of the progestin due to limited release of the progestin in the mouth. The progestin is hence not absorbed via the buccal route, but rather via the enteral (per-oral) route.

Abstract: The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and to minimise the content of polyvinylpyrrolidone, while still achieving similar fast dissolution of the estradiol. The dosage forms are useful in preventing or treating a physical condition in a woman caused by insufficient endogenous levels of estradiol.

Abstract: The present invention relates to drug delivery systems in the form of thin water-soluble films (wafers), which contain estradiol, or derivatives thereof, in low amounts. The wafers of the present invention are suitable for treating, alleviating or preventing a physical condition in a female mammal caused by insufficient endogenous levels of estrogen.

Abstract: A drug delivery system also intended as unit dosage form comprising a thin water-soluble film matrix, wherein said film matrix comprises a) a polyvinyl alcohol-polyethylene glycol graft copolymer (PVA-PEG graft co-polymer) as a water-soluble matrix polymer; an active ingredient being a steroid in which the positions 6 and 7 of the steroidal skeleton are both a —CH2— residue; and said film matrix has a thickness of less than 300 ?m.

Abstract: The invention relates to complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of ?-cyclodextrin, in particular a complex that consists of (thiazol-2-yl)-26,27-dinor-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol and heptakis-(2,6-di-O-methyl)-?-cyclodextrin (DIMEB).

Abstract: The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising non-micronized (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof.

Abstract: The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising micronised (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to oral solid dosage forms containing a very low dose of estradiol. The dosage forms are formulated in a manner so as to avoid degradation of the estradiol and to minimise the content of polyvinylpyrrolidone, while still achieving similar fast dissolution of the estradiol. The dosage forms are useful in preventing or treating a physical condition in a woman caused by insufficient endogenous levels of estradiol.

Abstract: Described are pharmaceutical compositions comprising at least one steroidal drug such as a progestin (e.g. drospirenone, progesterone, eplerenone, etonogestrel) and/or an estrogen (estradiol and esters thereof) in molecularly dispersed form. The composition comprises a steroidal drug, preferably drospirenone, which is present in the composition in a non-particulate form. Preferably, the drug is present in a dissolved state in the excipient. The molecularly dispersed drug will be released very fast as dissolution takes place instantly when the dosage unit has disintegrated. Also described are methods for preparing the pharmaceutical compositions and methods of using the compositions.

Abstract: Methods for improving solubility and bioavailability of lipophilic compounds are described. Particularly, described are stabilized superstaturated solid solutions, particularly in power form, of lipophilic drugs, such as steroidal molecules.

Abstract: A composition for use as penetration promoter in transdermal formulations for highly lipophilic active ingredients or active ingredient combinations, which comprises at least a first and a second penetration promoter, where the first penetration promoter is a monohydric or polyhydric alcohol, and the second penetration promoter is a saturated or unsaturated fatty acid having 8 to 18 carbon atoms or an ester or derivative thereof.